Bristol-Myers Squibb (BMY) Tops Q2 EPS by 43c, Beats on Revenue; Offers FY26 Guidance
Get Alerts BMY Hot Sheet
Price: $60.96 -1.17%
Revenue Growth %: +4.3%
Financial Fact:
Provision for income taxes: 344M
Today's EPS Names:
OMID, BCML, CZNC, More
Revenue Growth %: +4.3%
Financial Fact:
Provision for income taxes: 344M
Today's EPS Names:
OMID, BCML, CZNC, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $2.04, $0.43 better than the analyst estimate of $1.61. Revenue for the quarter came in at $12.97 billion versus the consensus estimate of $11.71 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2026 EPS of $6.75-$7.00, versus the consensus of $6.34. Bristol-Myers Squibb sees FY2026 revenue of $49.5-50 billion, versus the consensus of $47.5 billion.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- US Treasury: 'Authorizing Wind Down Activities...the Offloading of Cargo Involving Certain Persons or Vessels Blocked on October 21, 2026'
- StoneX Starts Gowell Energy Technology (GOW) at Buy
- Winnebago Industries (WGO) Misses Q4 EPS by 2c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share